Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of di...

Full description

Bibliographic Details
Main Authors:	Mackey, J., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W., Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in
Format:	Journal Article
Published:	Oxford University Press 2016
Online Access:	http://hdl.handle.net/20.500.11937/58543

_version_	1848760286342807552
author	Mackey, J. Pienkowski, T. Crown, J. Sadeghi, S. Martin, M. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Houé, V. Buyse, M. Drevot, P. Hitier, S. Bensfia, S. Eiermann, W. Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in
author_facet	Mackey, J. Pienkowski, T. Crown, J. Sadeghi, S. Martin, M. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Houé, V. Buyse, M. Drevot, P. Hitier, S. Bensfia, S. Eiermann, W. Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in
author_sort	Mackey, J.
building	Curtin Institutional Repository
collection	Online Access
description	BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety. PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC ? T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography. RESULTS: The 10-year DFS rates were 66.5% in the AC ? T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC ? T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC ? T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy. CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC ? T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208.
first_indexed	2025-11-14T10:13:22Z
format	Journal Article
id	curtin-20.500.11937-58543
institution	Curtin University Malaysia
institution_category	Local University
last_indexed	2025-11-14T10:13:22Z
publishDate	2016
publisher	Oxford University Press
recordtype	eprints
repository_type	Digital Repository
spelling	curtin-20.500.11937-585432017-11-24T05:46:19Z Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Mackey, J. Pienkowski, T. Crown, J. Sadeghi, S. Martin, M. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Houé, V. Buyse, M. Drevot, P. Hitier, S. Bensfia, S. Eiermann, W. Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety. PATIENTS AND METHODS: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC ? T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography. RESULTS: The 10-year DFS rates were 66.5% in the AC ? T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC ? T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC ? T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy. CONCLUSION: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC ? T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00312208. 2016 Journal Article http://hdl.handle.net/20.500.11937/58543 10.1093/annonc/mdw098 Oxford University Press unknown
spellingShingle	Mackey, J. Pienkowski, T. Crown, J. Sadeghi, S. Martin, M. Chan, Arlene Saleh, M. Sehdev, S. Provencher, L. Semiglazov, V. Press, M. Sauter, G. Lindsay, M. Houé, V. Buyse, M. Drevot, P. Hitier, S. Bensfia, S. Eiermann, W. Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title_full	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title_fullStr	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title_full_unstemmed	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title_short	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
title_sort	long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: bcirg-005 randomized trial.
url	http://hdl.handle.net/20.500.11937/58543

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

Similar Items